Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features.

Belén Sierro-MartínezVirginia Escamilla-GómezLaura Pérez-OrtegaBeatriz Guijarro-AlbaladejoPaola Hernández-DíazMaría de la Rosa-GarridoMaribel Lara-ChicaAlfonso Rodríguez-GilJuan Luis Reguera-OrtegaLuzalba Sanoja-FloresBlanca Arribas-ArribasMiguel Ángel Montiel-AguileraGloria CarmonaMaria Jose RoblesTeresa Caballero-VelázquezJavier BrionesHermann EinseleMichael HudecekJosé Antonio Pérez-Simón Estefanía García-Guerrero

Published in: Cellular oncology (Dordrecht, Netherlands) (2024)

CARTemis-1 has been rationally designed to increase antitumor efficacy, overcome sBCMA inhibition, and incorporate the expression of a safety-gene. The generation of CARTemis-1 was successfully validated under GMP standards. A phase I/II clinical trial for patients with multiple myeloma will be conducted (EuCT number 2022-503063-15-00).

Keyphrases

clinical trial
multiple myeloma
poor prognosis
copy number
genome wide
cancer therapy
minimally invasive
phase ii
study protocol
biofilm formation
double blind
genome wide identification
binding protein
randomized controlled trial
phase iii
escherichia coli
gene expression